IMAC Holdings Introduces Ignite Proteomics: A New Standard for Matching Patients with the Right Cancer Therapies
Rhea-AI Summary
IMAC Holdings (NASDAQ: BACK) has launched Ignite Proteomics , a subsidiary focused on protein-based cancer treatment selection. The new venture aims to disrupt the multi-billion-dollar genomic testing market, with an immediate addressable market of $600M in its current clinically approved indication.
Unlike traditional genomic testing, Ignite's multi-protein test provides real-time insights into tumor behavior and drug response, particularly for antibody-drug conjugates (ADCs) and immunotherapies. The platform features novel biomarkers protected by licensed patents, offering physicians enhanced capabilities to select effective treatments and avoid trial-and-error approaches.
The company is actively collaborating with leading cancer centers to expand clinical evidence and integrate its test into routine care. The platform is particularly focused on breast cancer treatment guidelines and aims to provide more accurate insights than traditional gene-based testing methods.
Positive
- Addressable market of $600M in current clinically approved indication
- Protected intellectual property through licensed patents for novel biomarkers
- Active collaborations with leading cancer centers
- Positioning to disrupt multi-billion-dollar genomic testing market
Negative
- None.
News Market Reaction
On the day this news was published, BACK gained 47.17%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Nashville, TN, Jan. 27, 2025 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: BACK) (“IMAC Holdings” or the “Company”) has launched Ignite Proteomics LLC (“Ignite”), its new subsidiary dedicated to helping doctors select the most effective cancer treatments based on protein-level insights. This move addresses a growing need for better, faster ways to personalize therapy in breast cancer and beyond.
Why Proteins Matter – Beyond Genomics
Although genomics (gene-based) testing has become common, patients and providers find it has not fully delivered on the promise of personalized care. One reason is that genetics only reveal potential – the blueprint of the disease – while proteins show what is happening inside cancer cells right now. Ignite is poised to disrupt the multi-billion-dollar genomic testing market. The available market in the test’s current clinically approved indication is
Proteins drive cell behavior and are the direct targets of many new cancer drugs, especially antibody-drug conjugates (ADCs) and immunotherapies. Without measuring key proteins, standard genomic tests can miss crucial signals that predict how a tumor will respond – or fail to respond – to treatment.
Ignite’s multi-protein test addresses this gap. By measuring a range of proteins in a single sample, it offers a richer view of a tumor’s activity and vulnerability to specific therapies. Several of the assay’s important novel biomarkers are protected by licensed patents, ensuring a unique platform for guiding advanced treatment choices.
“Gene tests alone don’t tell us enough about how to pick the right therapies,” said Faith Zaslavsky, CEO of IMAC Holdings and Ignite Proteomics. “Proteins are what guide a cancer’s behavior and drug response. Our test focuses on these real-time signals, so doctors can better select complex treatments right from the start.”
A Better Approach to Modern Cancer Treatments
Today’s advanced therapies—from new ADCs to immunotherapies—are more complex than traditional chemo. Standard “one-marker” tests often fail to identify which patients can truly benefit. Ignite’s test reviews multiple critical proteins at once, helping physicians:
- Spot lower levels of drug targets that standard methods might overlook.
- Determine whether an immunotherapy is likely to work—or if a patient would do better with another option.
- Avoid the costly and time-consuming trial-and-error approach that can delay effective treatment.
Looking Ahead: Partnerships & Growth
- Active Collaborations: Ignite is working with leading cancer centers to expand clinical evidence and incorporate its test into more routine care.
- Expanding Impact: The test’s ability to measure what genes alone cannot detect is expected to fill a major gap in personalized oncology.
- Focus on ADCs & Immunotherapy: With more complex drugs rolling out each year, physicians need deeper insights into a tumor’s real-time behavior—and that is exactly where Ignite’s protein-level approach excels.
- Standard of care: Ignite’s protein analysis has generated and is expanding clinical data needed to be included in treatment guidelines for breast cancer.
About IMAC Holdings, Inc.
IMAC Holdings, Inc. strives to improve patient outcomes through innovative healthcare solutions. By combining strategic acquisitions and innovative technologies, IMAC Holdings remains committed to advancing personalized medicine. IMAC Holdings has begun the process to change its name and will soon be shown as IMAC Holdings, Inc, DBA Ignite Sciences, Inc.
About Ignite Proteomics
Ignite Proteomics LLC, a subsidiary of IMAC Holdings, specializes in protein-based analysis for cancer treatment guidance. Operating under a CLIA-accredited lab, Ignite provides a single test covering multiple markers to help doctors pinpoint the most suitable therapies, bridging the gap that gene-focused methods leave behind. Several key markers in the assay are protected by licensed patents.
Forward-Looking Statements
This press release contains statements that involve known and unknown risks, uncertainties, and other factors that could cause actual results to differ. Readers are cautioned not to place undue reliance on these statements. For more information, please review the Company’s SEC filings.
Contact Information:
Investors@imacholdings.com
FAQ
What is the market opportunity for IMAC Holdings' (BACK) Ignite Proteomics?
How does IMAC Holdings' (BACK) Ignite protein test differ from traditional genomic testing?
What types of cancer treatments does IMAC Holdings' (BACK) Ignite test specifically target?
What partnerships has IMAC Holdings (BACK) established for Ignite Proteomics?
What is the current clinical focus of IMAC Holdings' (BACK) Ignite platform?
